Pathology Research International

Research Article

Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance

Table 1

Subject characteristics.
ControlHIV-ISHIV-IRHIV-IR (treated)
( 𝑁 = 2 2 )( 𝑁 = 2 1 )( 𝑁 = 1 9 )( 𝑁 = 1 0 )
Gender (M/F)10/1213/88/114/6
Race/ethnicity (AA/H/C)2/2/1815/2/410/3/67/0/3
Age (y) 3 8 ± 1 . 5 4 1 ± 1 . 4 4 1 ± 1 . 5 4 1 ± 2 . 3
BMI (kg/m2) 2 5 . 5 ± . 9 2 8 ± 1 . 4 2 7 ± . 8 2 6 ± 1 . 0
Viral load (copies/mL)N/A 4 0 0 ( 4 0 ; 3 4 , 3 2 0 ) 5 0 ( 4 0 ; 1 6 , 2 9 1 ) 9 0 0 ( 4 0 ; 1 6 , 2 9 1 )
CD4+ cells (cells/mm3) 5 0 0 ± 6 5 . 3 5 3 0 ± 5 8 . 8 6 6 8 ± 7 3 . 8
PI, NRTI, NNRTI221
PI, NRTI1274
NRTI, NNRTI452
NRTI010
No HIV meds332
Triglycerides (mg/dL) 1 0 4 ± 1 0 . 5 1 3 2 ± 1 4 3 2 4 ± 7 9 2 5 9 ± 5 7
Insulin sensitivity (mg glucose/kg LBM/min) 1 0 . 6 ± 0 . 7 4 9 . 7 ± 0 . 4 3 4 . 4 ± 0 . 9 0 ∗ 4 . 3 ± 0 . 3
Values are means ± SEM except viral load which is expressed as median and range. AA: African American; C: Caucasian; H: Hispanic; PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; and NNRTI: nonnucleoside reverse transcriptase inhibitor. HIV-IS: insulin sensitivity HIV subjects. HIV-IR: insulin-resistant HIV subjects. HIV- IR (treated) denotes subjects with insulin resistance who were treated with rosiglitazone (8 mg/d for 12 weeks). Insulin sensitivity was determined with the hyperinuslinemic euglycemic clamp and is expressed as mg glucose per kg per lean body mass per minute. ∗ Insulin sensitivity in the HIV-IR group was lower than either the control or the HIV-IS group ( 𝑃 < . 0 0 1 ). The data on improvement in HIV-associated insulin resistance with rosiglitazone treatment has been previously reported [12].